UNIVERSAL-WELLNESS-LABS
Digital Health Certificates are happening. Governments, airlines and the industry at large need solutions to get the people moving freely and safely. Universal Wellness Labs creates a wearable for hand cleaning that holds the QR-code for Health Certificates. The user-friendly gadget serves as an alternative medium, and as a back-up for the QR-codes in smartphone apps or printed on paper.
Health Certificates, a.k.a. Immunity Passports, Vaccine Certificates, Green Passes and PCR tests come as QR-code for storage in apps in people’s smartphones or printed on paper.
Universal Wellness Labs foresees potential issues and uses NFC as a medium for the QR.
It pairs the Health Certificate with hand hygiene in one useful and user-friendly wearable dispenser for hand sanitizer: the Zpritzi.
Marinus Vander Slikke, CEO of Universal Wellness Labs: “A document as vital as a Health Certificate must have a back-up. Apps can crash. Smartphones can die. Paper-printed QR-codes are old world, prone to forgery and get lost easily.”
NFC is secure, contactless and works without electronics and networks.
A video-presentation of the Zpritzi concept is available at www.zpritzi.com .
Universal Wellness Labs recently presented its concept to the European Commission.
Marinus Vander Slikke: “We anticipate deeper negotiations soon. Sweden and Denmark have already endorsed NFC. However, we are also targeting the private sector like airlines, hotels, cruise ships and event organisers.”
Zpritzi is a slim, elongated and ergonomic designed wearable gadget. Made from recyclable ABS. Refillable with any sanitizer spray. An integrated encrypted NFC tag stores the QR-code. People wear it around their neck, or on their belt or hand-bag.
Zpritzi is low-cost and an ideal product for corporate branding: It verifies people’s health status, makes hand disinfection easy and is a promotional tool with lasting marketing effects.
A pilot study with 88 participants shows the efficacy of the Zpritzi. Users clean their hands 75% more often with a Zpritzi than with conventional portable bottles.
Marinus Vander Slikke: “Hand cleaning is a first line of defence against any kind of bacteria and viruses, including Covid. Both the public and the private sector require proof of health to enter their country or premises. A quick scan of the Zpritzi verifies people’s health status. And the big advantage is that people always go in with clean hands.”
“In the new normal people still want to be trendy and look smart. Similar to face masks, Zpritzi makes the Health Certificate and hand sanitizing cool.”
Zpritzi is created in cooperation with Design2Gather, an award winning Dutch design company (design2gather.com ).
Universal Wellness Labs OÜ is an Estonia based company that conceptualizes and designs products for personal health and wellness (universalwellnesslabs.com ).
###
View source version on businesswire.com: https://www.businesswire.com/news/home/20210505005604/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom